NCT01993173已完成3 期
Immunogenicity and Safety of Sanofi Pasteur's Tdap Combined Vaccine (ADACEL) as a Booster Dose, Versus Local DT Vaccine in Healthy Children or Versus Local Td Vaccine in Healthy Adolescents and Adults in China
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,440
- 试验地点
- 1
- 主要终点
- Percentage of participants with anti-tetanus antibody concentrations ≥ 0.1 IU/mL
研究概览
简要总结
The aim of the study is to assess the immunogenicity and safety profile of ADACEL compared to local adsorbed diphtheria and tetanus combined vaccine (local DT or local Td vaccine in participants in China.
Primary objective:
- To describe diphtheria and tetanus seroprotection rates and pertussis booster response rates induced by each of the study vaccines: ADACEL vaccine (in all study age groups), local DT vaccine (in children), and local Td vaccine (in adolescents and adults).
Secondary Objectives:
- To further describe in each group the immunogenicity of the study vaccines at baseline and 1 month after vaccination.
- To describe the safety of the study vaccines
详细描述
Study participants will receive a single booster dose of ADACEL (Tdap vaccine) or a single booster dose of local DT or local Td vaccine, depending on the age subgroup.
Immunogenicity will be assessed before and 28 days post-vaccination; safety profile will be assessed in all subjects up to Day 35 post vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 4 Years 至 64 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 4 through 64 years on day of inclusion
- •For children and adolescents (4 through 17 years): Informed consent form has been signed and dated by the parent(s) or another legally acceptable representative and assent form has been signed and dated by the subject if aged 8 through 17 years
- •For adults (18 years and over): Informed consent form has been signed and dated by the subject
- •Subject and parent / legally acceptable representative (for subjects up to 17 years) are able to attend all schedule visits and to comply with all trial procedures
- •According to China National Immunization Recommendations, written documentation of complete primary series and fourth dose of diphtheria, tetanus, pertussis (DTP) vaccine for subjects aged 4 through 7 years and a written documentation or oral confirmation of complete primary series and fourth dose of DTP vaccine for subjects aged 8 through 64 years
排除标准
- •Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
- •Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine in the 4 weeks following the trial vaccination.
- •Previous vaccination against diphtheria and tetanus disease with either the trial vaccine or another vaccine (except Tetanus-prone wound management for adults) in the past 12 months.
- •Previous fifth vaccination against pertussis disease.
- •Receipt of immune globulins, blood or blood-derived products in the past 3 months.
- •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy.
- •Known (laboratory-confirmed / self-reported) Human Immunodeficiency Virus (HIV) or Hepatitis C seropositivity.
- •History of diphtheria, tetanus, or pertussis infection (confirmed either clinically, serologically or microbiologically).
- •Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
- •Laboratory-confirmed / self-reported thrombocytopenia, contraindicating intramuscular vaccination.
- •Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.
- •Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
- •Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.
- •Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 37.1°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
- •History of contra-indication to vaccination with pertussis containing vaccine, including:
- •Encephalopathy (e.g, coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis containing vaccine that is not attributable to another identifiable cause
- •Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy
- •Axillary temperature >39.4°C within 48 hours not attributable to another identifiable cause
- •Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours.
- •Prior personal history of Guillain-Barré syndrome.
- •Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
- •Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the vaccination and until at least 4 weeks after the vaccination.
结局指标
主要结局
Percentage of participants with anti-tetanus antibody concentrations ≥ 0.1 IU/mL
时间窗: 28 Days post-vaccination
Anti-tetanus antibody concentrations will be determined by enzyme-linked immunosorbent assay (ELISA)
Percentage of participants with anti-diphtheria antibody concentrations ≥ 0.1 international unit (IU)/mL
时间窗: 28 Days post-vaccination
Anti-diphtheria antibody concentrations will be determined by enzyme-linked immunosorbent assay (ELISA)
Percentage of participants with a booster response for antibodies to Pertussis Toxoid (PT), Filamentous hemagglutinin (FHA), pertactin (PRN), Fimbriae types 2 and 3 (FIM) following vaccination with ADACEL or Local DT or Local Td Vaccine
时间窗: Day 0 (pre-vaccination) and Day 28 post-vaccination
Booster response for antibodies to Pertussis Toxoid (PT), Filamentous hemagglutinin (FHA), pertactin (PRN), Fimbriae types 2 and 3 (FIM) will be determined by enzyme-linked immunosorbent assay (ELISA)
次要结局
- Percentage of participants with anti diphtheria antibody concentrations ≥ 0.1 international unit (IU)/mL at baseline(Day 0 (pre-vaccination))
- Percentage of participants with anti-tetanus antibody concentrations ≥ 0.1 IU/mL at baseline(Day 0 (pre-vaccination))
- Percentage of participants with anti-diphtheria antibody concentrations ≥ 1.0 international unit (IU)/mL at baseline and post booster vaccination(Day 0 (pre-vaccination) and Day 28 post-vaccination)
- Percentage of participants with anti-tetanus antibody concentrations ≥ 1.0 IU/mL at baseline and post booster vaccination(Day 0 (pre-vaccination) and Day 28 post-vaccination)
- Number of participants reporting solicited injection site reactions, solicited systemic reactions, unsolicited adverse reactions, and serious adverse events occurring during the trial(Day 0 up to Day 28 post-vaccination)
- Geometric mean of individual antibody concentrations at baseline and post-booster vaccination(Day 0 (pre-vaccination) and Day 28 post-vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended VaccinePolioHaemophilus Influenzae Type bWhooping CoughTetanusDiphtheriaNCT00662870Sanofi1,941
已完成
3 期
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsPolioHuman Immunodeficiency Virus InfectionHepatitis BTetanusDiphtheriaPertussisNCT02817451Sanofi Pasteur, a Sanofi Company53
已完成
3 期
Immunogenicity and Safety of ADACEL™ as Fifth Dose in TaiwanPertussisTetanusDiphtheriaNCT00258908Sanofi Pasteur, a Sanofi Company115
已完成
4 期
Study of Adacel® Vaccine Administered to Persons 10 Years of AgeTetanusPertussisDiphtheriaNCT01311557Sanofi1,302
已完成
3 期
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After BirthPoliomyelitisHaemophilus Influenzae Type bHepatitis BPertussisTetanusDiphtheriaNCT02428491Sanofi Pasteur, a Sanofi Company354